Literature DB >> 29088405

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer.

K Otsubo1, N Seki1, Y Nakanishi1, I Okamoto2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29088405     DOI： 10.1093/annonc/mdx700

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis.

Authors:  Suneel D Kamath; Priya U Kumthekar; Tim J Kruser; Nisha A Mohindra
Journal:  Oncologist       Date:  2018-08-02

2.  Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.

Authors:  Junjie Zhen; Lei Wen; Mingyao Lai; Zhaoming Zhou; Changguo Shan; Shaoqun Li; Tao Lin; Jie Wu; Wensheng Wang; Shaoqiang Xu; Da Liu; Ming Lu; Dan Zhu; Longhua Chen; Linbo Cai; Cheng Zhou
Journal:  Radiat Oncol       Date:  2020-07-31       Impact factor: 3.481

Review 3.  Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.

Authors:  Ana Turkaj; Anna M Morelli; Tiziana Vavalà; Silvia Novello
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.